Additional Indications Below for Module 4 and 5 clinical trials at University of California Health

1 in progress, 0 open to eligible people

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Sorry, not currently recruiting here
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
at UCSF

Last updated: June 3, 2022